The complexities of insulin allergy: a case and approach
Tóm tắt
Insulin hypersensitivity is rare, but challenging for individuals with diabetes. The prevalence of insulin allergy has decreased since the introduction of human recombinant insulin preparations. Hypersensitivity reactions range from injection site erythema and swelling, to anaphylaxis. While some reactions are to excipients (zinc, protamine, metacresol), many are to recombinant insulin itself. We present a case of type 1 hypersensitivity to various preparations of insulin in a patient with insulin-dependent type 2 diabetes mellitus (T2DM). A 61-year-old woman with a 30-year history of insulin-dependent T2DM was referred for evaluation of reactions to insulin. She had two episodes over 5-months; both required Emergency Department visits and epinephrine administration. The first episode entailed a burning sensation of the extremities and nausea, immediately after injecting NovoRapid® insulin. The second event entailed a similar reaction but this time there was also angioedema of the upper airway with difficulty breathing and hypotension, immediately after injecting Levemir® and NovoRapid®, and taking metformin. There were no cofactors such as exercise, infectious illness, or NSAIDs use. Skin testing was performed with metformin, Lantus®, Humalog®, NovoRapid®, glulisine, insulin regular, NPH, Levemir® and the excipient protamine, as per published testing concentrations. Metacresol was not tested as its use was restricted by the hospital pharmacy. Insulin preparations with and without metacresol were included in testing however. A clinic staff served as a negative control. The patent had negative testing with protamine, but sensitization to all insulin preparations. Metformin skin testing and challenge along with latex IgE were negative. Subsequently, she underwent intentional weight loss of 70 lb, and was started on oral hypoglycemics with good effect. Our case highlights the importance of diagnosing insulin allergy through a detailed history and focused testing. Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
Tài liệu tham khảo
Ladisch MR, Kohlmann KL. Recombinant human insulin. Biotechnol Prog. 1992;8(6):469–78.
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449–62.
Yuan T, Zhao W, Wang L, Dong Y, Li N. Continuous subcutaneous insulin infusion as an effective method of desensitization therapy for diabetic patients with insulin allergy: a 4-year single-center experience. Clin Ther. 2016;38(11):2489–94.
Castera V, Dutour-Meyer A, Koeppel MC, Petitjean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab. 2005;31(4):391–400.
Radermecker R, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev. 2007;23(5):348–55.
Mastrorilli C, Rizzuti L, Cangelosi AM, Iovane B, Chiari G, Caffarelli C. Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol. 2017;30(2):174–7.
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(Supplement 3):155–65.
Wheeler BJ, Taylor BJ. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report. J Med Case Rep. 2012;6(1):263.
Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy. 2008;63(2):148–55.
Raap U, Liekenbröcker T, Kapp A, Wedi B. Delayed-type hypersensitivity to protamine as a complication of insulin therapy. Contact Dermat. 2005;53(1):57–8.
Feinglos M, Jegasothy B. “Insulin” allergy due to zinc. Lancet. 1979;313(8108):122–4.
Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, Villaverde A. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact. 2016;15(1):33.
Fernandez L, Duque S, Montalban C, Bartolome B. Allergy to human insulin. Allergy. 2003;58(12):1317.
deShazo RD, Boehm TM, Kumar D, Galloway JA, Dvorak HF. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol. 1982;69(2):229–37.
Mandrup-Poulsen T, Mølvig J, Pildal J, Rasmussen ÅK, Andersen L, Skov BG, Petersen J. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia. Diabetes Care. 2002;25(1):242–3.
Alvarez-Thull L, Rosenwasser LJ, Brodie TD. Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin. Ann Allergy Asthma Immunol. 1996;76(3):253–6.
Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes. 1990;39(6):728–33.
Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci. 1997;86(5):517–25.
Maislos M, Mead PM, Gaynor DH, Robbins DC. The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. J Clin Investig. 1986;77(3):717–23.
Hasselmann C, Pecquet C, Bismuth E, Raverdy C, Sola-Gazagnes A, Lobut JB, Carel JC, Tubiana-Rufi N. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy. Diabetes Metab. 2013;39(2):174–7.
Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 1996;45(12):1750–4.
Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. N Engl J Med. 2006;354(3):307–9.
Roest MA, Shaw S, Orton DI. Insulin–injection–site reactions associated with Type I latex allergy. N Engl J Med. 2003;348(3):265–6.
Hasani-Ranjbar S, Fazlollahi MR, Mehri A, Larijani B. Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature. Acta Diabetol. 2012;49(1):69–73.
Pérez E, González R, Martínez J, Iglesias J, Matheu V. Detemir insulin–induced anaphylaxis. Ann Allergy Asthma Immunol. 2009;102(2):174–5.
Jacquier J, Chik CL, Senior PA. A practical, clinical approach to the assessment and management of suspected insulin allergy. Diabet Med. 2013;30(8):977–85.
Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract. 2017;5(5):1194–205.
Andrade P, Barros L, Gonçalo M. Type 1 IgE mediated allergy to human insulin, insulin analogues and beta-lactam antibiotics. An Bras Dermatol. 2012;87(6):917–9.
Wu P, Ji C, Wang M, Zou S, Ge W. Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine. In: Annales d'endocrinologie; 2013. Vol. 74, No. 1. pp. 56–8.
Grant W, DeShazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes care. 1986;9(3):318–9.
Cockel R, Mann S. Insulin allergy treated by low-dosage hydrocortisone. British Med J. 1967;3(5567):722.
Chng HH, Leong KP, Loh KC. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy. 1995;50(12):984–7.
Witters LA, Ohman JL, Weir GC, Raymond LW, Lowell FC. Insulin antibodies in the pathogenesis of insulin allergy and resistance. The American journal of medicine. 1977;63(5):703–9.
Gin H, Aubertin J. Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump. Diabetes Care. 1987;10(6):789–90.
Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes research and clinical practice. 2003;61(3):161–6.
Moyes V, Driver R, Croom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabetic medicine. 2006;23(2):204–6.
Näf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I, Gomis R. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care. 2002 Mar 1;25(3):634-5.
Matheu V, Perez E, Hernández M, Díaz E, Darias R, González A, García JC, Sánchez I, Feliciano L, Caballero A, De la Torre F. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clinical and Molecular Allergy. 2005;3(1):16.
Matheu V, Franco A, Perez E, Hernández M, Barrios Y. Omalizumab for drug allergy. Journal of Allergy and Clinical Immunology. 2007;120(6):1471.
Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabetic Medicine. 2018;35(5):663–6.
Yong PF, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MA, Gough A. Rituximab and omalizumab in severe, refractory insulin allergy. New England J Med. 2009;360(10):1045–7.
Malaise J, Leonet J, Goffin E, Lefebvre C, Tennstedt D, Vandeleene B, Buysschaert M, Squifflet JP. Pancreas transplantation for treatment of generalized allergy to human insulin in type 1 diabetes. In: Transplantation proceedings; 2005. Vol. 37, No. 6. pp. 2839.
Léonet J, Malaise J, Squifflet JP. Refractory insulin allergy: pancreas transplantation or immunosuppressive therapy alone?. Transplant Int. 2010;23(7):e39–40.